Literature DB >> 19403779

Campylobacter concisus: a new character in the Crohn's disease story?

Mario Guslandi, Li Zhang, Si Ming Man, Andrew S Day, Steven T Leach, Daniel A Lemberg, Shoma Dutt, Michael Stormon, Anthony Otley, Edward V O'Loughlin, Annabel Magoffin, Patrick H Y Ng, Hazel Mitchell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19403779      PMCID： PMC2681860          DOI： 10.1128/JCM.00310-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  7 in total

Review 1.  Antibiotics for inflammatory bowel disease: do they work?

Authors:  Mario Guslandi
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

2.  "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy.

Authors:  David B Doman; Howard J Goldberg; Martin I Golding
Journal:  Am J Gastroenterol       Date:  2008-01       Impact factor: 10.864

3.  An open-label evaluation of rifaximin in the treatment of active Crohn's disease.

Authors:  Ira Shafran; Lorin K Johnson
Journal:  Curr Med Res Opin       Date:  2005-08       Impact factor: 2.580

Review 4.  Campylobacter concisus: an emerging pathogen?

Authors:  Diane G Newell
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-10       Impact factor: 2.566

5.  Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

Authors:  C Prantera; H Lochs; M Campieri; M L Scribano; G C Sturniolo; F Castiglione; M Cottone
Journal:  Aliment Pharmacol Ther       Date:  2006-04-15       Impact factor: 8.171

6.  Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease.

Authors:  Li Zhang; Si Ming Man; Andrew S Day; Steven T Leach; Daniel A Lemberg; Shoma Dutt; Michael Stormon; Anthony Otley; Edward V O'Loughlin; Annabel Magoffin; Patrick H Y Ng; Hazel Mitchell
Journal:  J Clin Microbiol       Date:  2008-12-03       Impact factor: 5.948

Review 7.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546
  7 in total
  1 in total

Review 1.  Campylobacter concisus - A new player in intestinal disease.

Authors:  Nadeem Omar Kaakoush; Hazel Marjory Mitchell
Journal:  Front Cell Infect Microbiol       Date:  2012-02-03       Impact factor: 5.293
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.